We are a clinical-stage biopharmaceutical company
developing novel fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, metabolic dysfunction-associated steatohepatitis (MASH), and certain FASN-dependent tumor types.
Denifanstat
Our lead product candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor with a differentiated method of action with the potential to target multiple underserved diseases. Strong clinical data demonstrates denifanstat’s proof of concept across multiple disease states. Sagimet plans to file an Investigational New Drug (IND) Application for denifanstat for the treatment of moderate to severe acne in mid-2026. Following IND clearance, Sagimet anticipates advancing denifanstat into a registrational Phase 3 trial in moderate to severe acne patients in 2H 2026.
Development Pipeline: Indications and Clinical Milestones
Stage of Development
Therapeutic area
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Dermatology
Metabolic
disease
*FASN inhibitor Topical Formulation
